[Chinese Expert Consensus on Diagnosis and Treatment of Non-small Cell Lung Cancer with MET Abnormality (2026 Version)].

内容摘要

The mesenchymal-epithelial transition factor (MET) gene, located on human chromosome 7, exerts critical regulatory roles in cellular processes including proliferation, migration, invasion, and angiogenesis. As a key driver gene in non-small cell lung cancer (NSCLC), MET abnormalities encompass MET exon 14 (METex14) skipping mutations, gene amplification, protein overexpression, gene fusions, and activating mutations. This consensus, developed by the Lung Cancer Specialty Committee of the Chinese Elderly Health Care Association, updates the 2025 version with several key modifications: elevating the recommendation level for MET amplification and protein overexpression testing, advocating routine testing for all newly diagnosed NSCLC patients and those with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs); standardizing targeted therapy approaches for MET amplification in driver gene-negative settings and following EGFR-TKIs resistance; and subdividing MET protein overexpression-related management into post-EGFR-TKIs resistance and driver gene-negative categories with corresponding treatment protocols, thereby offering more actionable guidance for precise clinical decision-making.
. 【中文题目：MET异常非小细胞肺癌诊疗中国专家共识（2026年版）】 【中文摘要：间质上皮细胞转化因子（mesenchymal-epithelial transition factor, MET）基因位于人类第7号染色体，在细胞增殖、迁移、侵袭及血管新生等生理过程中发挥关键调节作用。作为非小细胞肺癌（non-small cell lung cancer, NSCLC）的主要驱动基因之一，MET异常可表现为MET基因14号外显子（MET exon 14, METex14）跳跃突变、基因拷贝数扩增、蛋白水平过表达、基因融合及活化突变等多种形式。本共识由中国老年保健协会肺癌专业委员会牵头，在2025版基础上进行了重要更新：提高MET扩增与蛋白过表达检测的推荐级别，要求对所有初诊及表皮生长因子受体-酪氨酸激酶抑制剂（epidermal growth factor receptor-tyrosine kinase inhibitors, EGFR-TKIs）耐药后的NSCLC患者常规开展这两项检测；规范了驱动基因阴性和EGFR-TKIs耐药后MET扩增的靶向治疗策略；针对MET蛋白过表达，分别就MET-TKIs耐药后与驱动基因阴性两种情境给出具体治疗建议，旨在为临床精准治疗提供更具操作性的参考。
】 【中文关键词：肺肿瘤；MET异常；METex14跳跃突变；MET扩增；MET蛋白过表达；靶向治疗；MET-TKIs】.